ArticleEuropean journal of public health2025
Hepatitis B and C landscape in Uzbekistan: epidemiological patterns revealed in a study of 1 040 000 people.
Article in European journal of public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Prevalence and epidemiology of hepatitis C in Uzbekistan: results from a population-based serosurvey, 2022.IJID regions · 2026Article
- Hepatitis B and D burden in Uzbekistan: comprehensive analysis of seroprevalence and risk correlates from a countrywide study.Infectious diseases of poverty · 2026Article
- High Rates of Advanced Chronic Liver Disease in Patients With Chronic Hepatitis D Virus Infection in Uzbekistan.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Uzbekistan initiated a nationwide screening program for viral hepatitis B (HBV) and C (HCV) in response to the global call for viral hepatitis elimination by 2030. This study aimed to assess HBV and HCV prevalence among the general population, provide treatment for diagnosed cases, and evaluate the effectiveness of direct-acting antiviral (DAA) therapy for HCV. From July 2022 to June 2024, 1 048 575 individuals aged 1-95 years were screened at local healthcare facilities using rapid immunochromatographic tests for hepatitis B surface antigen (HBsAg) and antibodies against hepatitis C virus (anti-HCV). Positive cases underwent confirmatory testing and were linked to care. HCV RNA-positive patients were assessed for DAA treatment eligibility. Overall HBsAg prevalence was 2.89% and anti-HCV prevalence was 3.52%. HBV prevalence decreased from 3.25% in those born before 2000 to 0.77% in those born after (P < .01), reflecting the impact of the national HBV vaccination program. Of 32 132 anti-HCV positive individuals, 20 039 (62.4%) were confirmed HCV RNA positive. Among these, 18 327 were eligible for DAA treatment. The majority received a 12-week treatment course, while 2126 (11%) with advanced liver fibrosis received a 24-week regimen. The sustained virological response rate was high, with only 1.17% of patients with advanced fibrosis and 0.96% without advanced fibrosis failing to achieve viral clearance. This large-scale study demonstrates the effectiveness of Uzbekistan's HBV vaccination program and the success of DAA treatment in achieving high cure rates for HCV. The study provides crucial data to guide public health strategies for combating viral hepatitis in Uzbekistan and progressing towards the World Health Organization's 2030 elimination targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.